Medication-related issues associated with adherence to long-term tyrosine kinase inhibitors for controlling chronic myeloid leukemia: a qualitative study

References

• HoglundMSandinFSimonssonBEpidemiology of chronic myeloid leukaemia: an updateAnn Hematol201594Suppl 2S241S24725814090
   PubMed Web of Science ®Google Scholar
• OmarZAIbrahim TaminNSNational Cancer Registry Report 2007Kuala LumpurMinistry of Health Malaysia2011
   Google Scholar
• BeePCSekaranVNgRRKwehTYGanGGThe predictive value of early molecular response in chronic myeloid leukaemia patients treated with imatinib in a single real-world medical centre in a developing countrySingapore Med J201758311628111689
   PubMed Web of Science ®Google Scholar
• MahonFXReaDGuilhotJDiscontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trialLancet Oncol201011111029103520965785
   PubMed Web of Science ®Google Scholar
• RossDMBranfordSSeymourJFSafety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER studyBlood2013122451552223704092
   PubMed Web of Science ®Google Scholar
• O’BrienSRadichJPAbboudCNChronic myelogenous leukemia, version 1.2014J Natl Compr Canc Netw201311111327134024225967
   PubMed Web of Science ®Google Scholar
• NoensLHensenMKucmin-BemelmansIMeasurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: current situation and future challengesHaematologica201499343744724598855
   PubMed Web of Science ®Google Scholar
• IbrahimAREliassonLApperleyJFPoor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapyBlood2011117143733373621346253
   PubMed Web of Science ®Google Scholar
• MarinDBazeosAMahonFXAdherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinibJ Clin Oncol201028142381238820385986
   PubMed Web of Science ®Google Scholar
• ChenTCChenLCHuangYBChangCSImatinib adherence associated clinical outcomes of chronic myeloid leukaemia treatment in TaiwanInt J Clin Pharm201436117218124242992
   PubMed Web of Science ®Google Scholar
• DarkowTHenkHJThomasSKTreatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemiaPharmacoeconomics200725648149617523753
   PubMed Web of Science ®Google Scholar
• LamMSCheungNImpact of oncology pharmacist-managed oral anticancer therapy in patients with chronic myelogenous leukemiaJ Oncol Pharm Pract201622674174826419691
   PubMed Web of Science ®Google Scholar
• KekaleMTalvensaariKKoskenvesaPPorkkaKAiraksinenMChronic myeloid leukemia patients’ adherence to peroral tyrosine kinase inhibitors compared with adherence as estimated by their physiciansPatient Prefer Adherence201481619162725473270
   PubMed Web of Science ®Google Scholar
• WuSCheeDUgaldeAButowPSeymourJSchofieldPLack of congruence between patients’ and health professionals’ perspectives of adherence to imatinib therapy in treatment of chronic myeloid leukemia: a qualitative studyPalliat Support Care201513225526324524212
   PubMed Web of Science ®Google Scholar
• EfficaceFBrecciaMSausseleSWhich health-related quality of life aspects are important to patients with chronic myeloid leukemia receiving targeted therapies and to health care professionals? GIMEMA and EORTC Quality of Life GroupAnn Hematol20129191371138122543826
   PubMed Web of Science ®Google Scholar
• EliassonLCliffordSBarberNExploring chronic myeloid leukemia patients’ reasons for not adhering to the oral anticancer drug imatinib as prescribedLeuk Res201135562663021095002
   PubMed Web of Science ®Google Scholar
• ChenLCChenTCHuangYBChangCSDisease acceptance and adherence to imatinib in Taiwanese chronic myeloid leukaemia outpatientsInt J Clin Pharm201436112012724154825
   PubMed Web of Science ®Google Scholar
• BurkhartPVSabatéEAdherence to long-term therapies: evidence for actionJ Nurs Scholarsh200335320714562485
   PubMed Web of Science ®Google Scholar
• BeePCGanGGTaiYTHarisARChinEVeeraSNAn update on imatinib mesylate therapy in chronic myeloid leukaemia patients in a teaching hospital in MalaysiaSingapore Med J2012531576122252185
   PubMed Web of Science ®Google Scholar
• BalashankerSChenLCChuaSSEvaluating imatinib adherence in a hospital setting in MalaysiaPoster presented at: EuroDURG ConferenceAugust 27–29, 2014Groningen, Netherlands
   Google Scholar
• BalashankerSChenLCTaylorCADeterminants of Patient Adherence to ImatinibPharmacoepidemiol Drug Saf201524S1493
   Google Scholar
• KuperAReevesSLevinsonWAn introduction to reading and appraising qualitative researchBMJ2008337a28818687727
   PubMed Web of Science ®Google Scholar
• PalinkasLAHorwitzSMGreenCAWisdomJPDuanNHoagwoodKPurposeful sampling for qualitative data collection and analysis in mixed method implementation researchAdm Policy Ment Health201542553354424193818
   PubMed Web of Science ®Google Scholar
• GaterAHeronLAbetz-WebbLAdherence to oral tyrosine kinase inhibitor therapies in chronic myeloid leukemiaLeuk Res201236781782522364811
   PubMed Web of Science ®Google Scholar
• BraunVClarkeVUsing thematic analysis in psychologyQual Res Psychol20063277101
   Google Scholar
• EfficaceFRostiGCottoneFProfiling chronic myeloid leukemia patients reporting intentional and unintentional non-adherence to lifelong therapy with tyrosine kinase inhibitorsLeuk Res201438329429823906625
   PubMed Web of Science ®Google Scholar
• HefnerJCsefEJKunzmannVFear of progression in outpatients with chronic myeloid leukemia on oral tyrosine kinase inhibitorsOncol Nurs Forum201643219019726906130
   PubMed Web of Science ®Google Scholar
• GanGGLeongYCBeePCComplementary and alternative medicine use in patients with hematological cancers in MalaysiaSupport Care Cancer20152382399240625876158
   PubMed Web of Science ®Google Scholar
• PalandriFCastagnettiFTestoniNChronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-upHaematologica200893121792179618838477
   PubMed Web of Science ®Google Scholar
• HalmEAMoraPLeventhalHNo symptoms, no asthma: the acute episodic disease belief is associated with poor self-management among inner-city adults with persistent asthmaChest2006129357358016537854
   PubMed Web of Science ®Google Scholar
• MoonJHSohnSKKimSNPatient counseling program to improve the compliance to imatinib in chronic myeloid leukemia patientsMed Oncol20122921179118521472487
   PubMed Web of Science ®Google Scholar
• HirjiIGuptaSGorenAChronic myeloid leukemia (CML): association of treatment satisfaction, negative medication experience and treatment restrictions with health outcomes, from the patient’s perspectiveHealth Qual Life Outcomes20131116724099272
   PubMed Web of Science ®Google Scholar
• BaerMNilotinib risk evaluation and mitigation strategyClin Adv Hematol Oncol20119753954022402461
   PubMedGoogle Scholar
• VervloetMLinnAJvan WeertJCde BakkerDHBouvyMLvan DijkLThe effectiveness of interventions using electronic reminders to improve adherence to chronic medication: a systematic review of the literatureJ Am Med Inform Assoc201219569670422534082
   PubMed Web of Science ®Google Scholar
• KodamaYMorozumiRMatsumuraTIncreased financial burden among patients with chronic myelogenous leukaemia receiving imatinib in Japan: a retrospective surveyBMC Cancer20121215222530992
   PubMed Web of Science ®Google Scholar